4.6 Article

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Immunology

Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B

Mina S. Farag et al.

Summary: During PEG-IFN treatment for HBeAg-negative CHB, HBV-RNA showed a rapid and significant decrease that correlated with treatment response and HBsAg loss at long-term follow-up.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Circulating Pregenomic Hepatitis B Virus RNA Is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue Therapy

Mark Anderson et al.

Summary: The study found that full-length pregenomic RNA is the primary source of circulating HBV RNA in infected patients, clarifying the major identity of HBV RNA species in circulation.

CLINICAL INFECTIOUS DISEASES (2021)

Article Gastroenterology & Hepatology

Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation

Wai-Kay Seto et al.

Summary: In patients with chronic HBV infection, measurement of serum HBV RNA is crucial in determining the suitability of cessation of entecavir treatment, especially for those with low HBsAg levels. Patients can be stratified based on viral determinants to assess their risk of off-treatment relapse.
Article Gastroenterology & Hepatology

What drives the dynamics of HBV RNA during treatment?

Antonio Goncalves et al.

Summary: The study developed a multiscale model of HBV to analyze the dynamics of HBV DNA and HBV RNA in patients treated with RG7907. RG7907 efficiently blocked encapsidation of HBV RNA, leading to decreases in both HBV DNA and HBV RNA, with their decline rates becoming consistent over time.

JOURNAL OF VIRAL HEPATITIS (2021)

Article Gastroenterology & Hepatology

HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy

Lung-Yi Mak et al.

Summary: This study explored the profile of HBV RNA in patients with chronic hepatitis B and its correlation with other viral markers. The results showed distinct profiles of HBV RNA in patients at different disease phases and its strong correlation with HBcrAg. NA treatment could effectively reduce serum HBV RNA levels in treatment-naive patients. Monitoring of viral activities through serum HBV RNA is still possible in patients with undetectable HBV DNA.

HEPATOLOGY (2021)

Article Gastroenterology & Hepatology

Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load

Tai-Chung Tseng et al.

Summary: In patients with chronic hepatitis B virus infection, higher levels of HBcrAg are associated with increased risk of cirrhosis. Among patients with intermediate viral load, HBcrAg <10 KU/mL defines a low-risk group for disease progression.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Article Gastroenterology & Hepatology

Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)

Seng Gee Lim et al.

Summary: This study evaluated the role of qHBsAg, HBV RNA, and qHBcrAg in predicting HBsAg loss in CHB patients, finding that on-treatment biomarker predictors were more effective than baseline ones. The best predictor of HBsAg loss at 72 weeks was a qHBsAg level <70 IU/mL at week 8.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Review Gastroenterology & Hepatology

Role of Biomarkers in Guiding Cure of Viral Hepatitis B

Maria Buti et al.

SEMINARS IN LIVER DISEASE (2020)

Article Gastroenterology & Hepatology

Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL

Tzu-Ning Tseng et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

Review Gastroenterology & Hepatology

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

Giovanni Raimondo et al.

JOURNAL OF HEPATOLOGY (2019)

Review Virology

Pregenomic RNA: How to assist the management of chronic hepatitis B?

Yongbin Wu et al.

REVIEWS IN MEDICAL VIROLOGY (2019)

Review Genetics & Heredity

The Role of Hepatitis B Core-Related Antigen

Takako Inoue et al.

Article Gastroenterology & Hepatology

Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues

Tetsuya Hosaka et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

Article Gastroenterology & Hepatology

Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk

Yao-Chun Hsu et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

Article Gastroenterology & Hepatology

New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection

Carla S. Coffin et al.

GASTROENTEROLOGY (2019)

Article Gastroenterology & Hepatology

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment

Margo J. H. van Campenhout et al.

HEPATOLOGY (2018)

Article Gastroenterology & Hepatology

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Norah A. Terrault et al.

HEPATOLOGY (2018)

Article Gastroenterology & Hepatology

Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay

Noboru Shinkai et al.

LIVER INTERNATIONAL (2017)

Article Gastroenterology & Hepatology

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

S. K. Sarin et al.

HEPATOLOGY INTERNATIONAL (2016)

Article Medicine, General & Internal

Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B

GKK Lau et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)